Korsana Biosciences
KRSA
31.65
-0.12
-0.38%
Korsana Biosciences
US · KRSA
#2830 by market cap
Listed 1970
31.65
-0.12
-0.38%
Live - 5344 symbols - heartbeat 145s ago
· 2026-10-08 02:52
After-hours
31.30
-1.11%
Overnight
31.65
0.00%
- Market cap
- 1.97B
- P/E (TTM)i
- -45.21
- P/Bi
- 4.40
- EPSi
- -0.70
- Div yieldi
- 0.00%
- 52W posi
- 47%
Reader sentiment
Are you bullish or bearish on KRSA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 2 years
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | -- | -- |
| Gross profit | -- | -- |
| Selling & admin expenses | 53.00K | 4.51M |
| Research & development | 56.00K | 32.79M |
| Operating profit | -109.00K | -37.29M |
| Pretax profit | -88.00K | -35.64M |
| Tax | -- | -- |
| Net profit | -88.00K | -35.64M |
| Basic EPS | 0 | -7 |
| Diluted EPS | -0.02 | -7.07 |
| Line item | 2026-06 |
|---|---|
| Revenue | -- |
| Gross profit | -- |
| Selling & admin expenses | 2.94M |
| Research & development | 15.51M |
| Operating profit | -18.45M |
| Pretax profit | -17.36M |
| Tax | -- |
| Net profit | -17.36M |
| Basic EPS | -3 |
| Diluted EPS | -3.42 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 10.11M | 154.60M |
| Cash & ST investments | 10.11M | 154.14M |
| Inventory | -- | -- |
| Total assets | 10.11M | 154.60M |
| Total current liabilities | 78.00K | 12.49M |
| Short-term debt | -- | -- |
| Long-term debt | -- | -- |
| Total liabilities | 10,042,000.00 | 188,564,000.00 |
| Total equity | 66.00K | -33.97M |
| Retained earnings | -88.00K | -35.73M |
| Line item | 2026-06 |
|---|---|
| Total current assets | 121.81M |
| Cash & ST investments | 121.17M |
| Inventory | -- |
| Total assets | 126.16M |
| Total current liabilities | 12.55M |
| Short-term debt | 191.00K |
| Long-term debt | -- |
| Total liabilities | 189,434,000.00 |
| Total equity | -63.28M |
| Retained earnings | -66.60M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | 44.00K | -22.41M |
| Depreciation & amortization | -- | -- |
| Free cash flow | 44.00K | -22.41M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 10.11M | 154.14M |
| Line item | 2026-06 |
|---|---|
| Operating cash flow | -- |
| Depreciation & amortization | -- |
| Free cash flow | -- |
| Dividends paid | -- |
| Stock buybacks / issuance | -- |
| Ending cash balance | -- |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -133.33 | -- |
| ROA %i | -0.87 | -43.28 |
| ROIC %i | -165.15 | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -- |
| FCF / sales %i | -- | -- |
| Current ratioi | 129.59 | 12.38 |
| Quick ratioi | 129.59 | 12.34 |
| Debt / assetsi | -- | -- |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2026-06 |
|---|---|
| ROE %i | -- |
| ROA %i | -- |
| ROIC %i | -- |
| 5-year avg ROE %i | -- |
| EBIT margin %i | -- |
| FCF / sales %i | -- |
| Current ratioi | 9.71 |
| Quick ratioi | 9.65 |
| Debt / assetsi | 0.88 |
| LT debt / equityi | -- |
| Interest coveragei | -- |
| Revenue CAGR (3Y) %i | -- |
| Net income CAGR (3Y) %i | -- |
| FCF CAGR (3Y) %i | -- |
Quote time 2026-10-08 02:52:54 · For reference only, not investment advice and not tailored to your situation.